Bijal D. Shah, MD, of the H. Lee Moffitt Cancer Center, discusses key studies of CAR T-cell therapy in relapsed B-cell ALL and the adverse events that this treatment may cause.
Anne M. Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the latest recommendations for screening and diagnosing hepatocellular carcinoma, an aggressive tumor marked by increasing incidence in the United States and a poor 5-year survival rate.
Anthony D. Elias, MD, of the University of Colorado Cancer Center, reviews promising experimental treatments, as well as PARP inhibitor therapy in TNBC, including the implications of newly approved olaparib for gBRCA-mutant breast cancer.
Lee N. Newcomer, MD, who recently retired as Senior Vice President for Oncology and Genetics at UnitedHealth Group, discusses lessons learned during his long career in managed care, where we are, and where we need to go.
April K.S. Salama, MD, of Duke Cancer Institute, talks about how to select systemic therapy for a patient with previously treated metastatic melanoma.
Ellin Berman, MD, of Memorial Sloan Kettering Cancer Center, discusses the effects of TKI therapy on fetal development, its impact on pregnancy outcomes, and how to develop an effective treatment plan.
